On May 28, 2026 Relmada Therapeutics, Inc. (Nasdaq: RLMD, "Relmada" or the "Company"), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, reported that Sergio Traversa, Chief Executive Officer, and Maged Shenouda, Chief Financial Officer, will participate in the Jefferies Global Healthcare Conference being held in New York, NY, from June 2-4, 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Jefferies Global Healthcare Conference Details
Format: Fireside Chat
Date: Thursday, June 4, 2026
Time: 12:50 PM ET
Webcast: Click Here

Management will also be available for one-on-one investor meetings during the conference. Please contact your Jefferies representative to schedule a meeting.

The webcast can also be accessed on the Events page of the Investors section of the Relmada website at View Source An archived replay will be available for 90 days following the conclusion of the event.

(Press release, Relmada Therapeutics, MAY 28, 2026, View Source [SID1234666152])

On May 28, 2026 Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the development and commercialization of ONS-5010/LYTENAVA (bevacizumab-vikg, bevacizumab gamma) for the treatment of retinal diseases, reported that it has entered into a definitive agreement providing for the purchase and sale of an aggregate of 8,539,709 shares of its common stock at a purchase price of $0.5855 per share in a registered direct offering priced at-the-market under Nasdaq rules to GMS Ventures and Investments, the Company’s largest stockholder. The closing of the offering is expected to occur on or about May 29, 2026, subject to the satisfaction of customary closing conditions. The aggregate gross proceeds to the Company from the offering are expected to be $5.0 million, before deducting offering expenses payable by the Company. The Company intends to use the net proceeds from this offering, together with existing cash and cash equivalents, for working capital and general corporate purposes.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The securities described above are being offered and sold by the Company in a registered direct offering pursuant to a "shelf" registration statement on Form S-3 (File No. 333-278340) that was originally filed with the Securities and Exchange Commission (the "SEC") on March 28, 2024, and that became effective on April 5, 2024. The offering of the securities in the registered direct offering is being made only by means of a base prospectus and prospectus supplement that forms a part of the effective registration statement. A final prospectus supplement and the accompanying base prospectus relating to the registered direct offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov. Electronic copies of the final prospectus supplement and the accompanying base prospectus, when available, may also be obtained, when available, from the Company at 111 S. Wood Avenue, Unit #100, Iselin, New Jersey 08830, by phone at (609) 619-3990 or e-mail at [email protected].

The Company also has agreed to amend certain outstanding common stock warrants to purchase up to an aggregate of 15,488,570 shares of common stock previously issued to GMS Ventures and Investments in January 2025 and May 2025, with a weighted average exercise price of $1.78 per share, effective upon the closing of the offering, such that the amended warrants will have a reduced exercise price of $0.5855 per share.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

(Press release, Outlook Therapeutics, MAY 28, 2026, View Source [SID1234666151])

On May 28, 2026 NETRIS Pharma, a clinical-stage oncology company targeting the netrin-1 / epithelial-to-mesenchymal transition (EMT) axis, reported that it has secured €7.25 million in funding under the European Union’s Horizon Europe programme to conduct a Phase 2b randomized clinical trial of NP137 in head and neck squamous cell carcinoma (HNSCC). The trial will be led by Principal Investigator Dr. Jérôme Fayette, MD, PhD, a medical oncologist at Centre Léon Bérard (Lyon, France), and conducted in partnership with GORTEC (Groupe Oncologie Radiothérapie Tête Et Cou), the leading French cooperative oncology group in HNSCC led by Professor Jean Bourhis and TTCC group, the Spanish group for the treatment of head and neck tumors, chaired by Dr. Ricard Mesia.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

« Head and neck squamous cell carcinoma remains a disease with significant unmet need, particularly with a large portion of patients relapsing under immunotherapy. The scientific rationale for targeting netrin-1 in HNSCC to alleviate resistance to immunotherapy and thus extend the survival of patients is compelling,and the clinical outcomes from the Phase2 ImmunoNET study confirms the potential of NP137 to deliver meaningful clinical benefit for our patients » said Dr. Jérôme Fayette, MD, PhD, Principal Investigator and Medical Oncologist at Centre Léon Bérard.

Patrick Mehlen, PhD, Chief Executive Officer of NETRIS Pharma, said: « We are delighted to receive this Horizon Europe grant, which is a further validation of both our scientific approach and our development strategy in head and neck cancer. NP137 is the only clinical-stage anti-netrin1 therapy, and HNSCC is a key indications given the resistance to current treatment. Conducting this Phase 2b study in partnership with GORTEC, the most experienced cooperative group in this field, and under the leadership of Dr. Fayette, provides the ideal framework to generate the high-quality clinical evidence needed to advance NP137 toward regulatory discussions. This funding reinforces our commitment to bringing truly differentiated therapies to patients with limited options ».

« GORTEC is proud to partner with NETRIS Pharma on this innovative Phase 2b programme. Head and neck cancer is a field where new mechanistic approaches are urgently needed. The netrin-1 / EMT axis represents a clinically actionable target, and we look forward to generating robust data in the context of this well-designed Horizon Europe-funded trial » said Professor Jean Bourhis, Chief Executive Officer and Chief Medical Officer of GORTEC.

The Horizon Europe programme is the European Union’s key funding mechanism for research and innovation. « Following the positive outcome of the immunonet study, this funding reflects the high value of NP137 in oncology », said Christophe Guichard, Chief Financial Officer of NETRIS Pharma. The funding will support the design, conduct and analysis of the Phase 2b randomized trial in HNSCC, building on the clinical evidence supporting the role of netrin-1 in driving treatment resistance in this indication. The project will be conducted through a consortium led by NETRIS Pharma with GORTEC, Grupo Español de Tratamiento de Tumores de Cabeza y Cuello – TTCC and Université Libre de Bruxelles.

About the Phase 2b HNSCC Trial

The Phase 2b trial is a randomized, multi-center study evaluating NP137 in patients with head and neck squamous cell carcinoma. The study will be conducted across multiple centers in France and Spain under the sponsorship of GORTEC, with Dr. Jérôme Fayette of Centre Léon Bérard serving as Principal Investigator. The trial design will incorporate translational endpoints aimed at further characterizing the role of netrin-1 and its receptors as predictive biomarkers of response to NP137, consistent with NETRIS Pharma’s precision oncology development strategy.

Full details of the trial design, including patient population, primary and secondary endpoints, and treatment schedule, will be disclosed at the time of trial initiation.

About Head and Neck Squamous Cell Carcinoma (HNSCC)

Head and neck squamous cell carcinoma (HNSCC) encompasses cancers of the oral cavity, pharynx, larynx, and other structures of the upper aerodigestive tract. It represents the sixth most common cancer worldwide, with approximately 900,000 new cases and 450,000 deaths annually. Despite advances in surgery, radiotherapy, and systemic therapy including checkpoint inhibitor immunotherapy, outcomes for patients with recurrent and/or metastatic HNSCC remain poor, with median overall survival of approximately 14–15 months with current standard-of-care regimens.

NETRIS Pharma has established a scientific rationale for netrin-1 blockade in HNSCC based on the role of netrin-1 in driving epithelial-to-mesenchymal transition (EMT) and acquired resistance to treatment, mechanisms that are highly relevant in this tumor type. NP137 is currently in clinical development in HNSCC as part of NETRIS Pharma’s broader multi-indication development strategy.

About GORTEC

GORTEC (Groupe Oncologie Radiothérapie Tête Et Cou) is the leading French cooperative oncology group dedicated to the clinical development of innovative treatments for head and neck cancers. GORTEC has conducted numerous landmark clinical trials in HNSCC and is widely recognized as one of the most prolific and scientifically rigorous cooperative groups in this field in Europe. The group is led by Professor Jean Bourhis, a world-leading expert in head and neck oncology and radiation oncology.

(Press release, Netris Pharma, MAY 28, 2026, View Source [SID1234666150])

On May 28, 2026 Merck (NYSE: MRK), known as MSD outside of the United States and Canada, reported that Dr. Marjorie Green, senior vice president and head of oncology, global clinical development, Merck Research Laboratories, is scheduled to participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 4, 2026, at 10:30 a.m. ET.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Investors, analysts, members of the media and the general public are invited to listen to a live audio webcast of the presentation at this weblink.

(Press release, Merck & Co, MAY 28, 2026, View Source [SID1234666149])

On May 28, 2026 Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (TSX: MDNA), a clinical stage immunotherapy company focused on the development of Superkines targeting cancer and autoimmune diseases, reported the closing of its previously announced marketed public offering of units (the "Units") of the Company at a price to the public of CDN$0.50 per Unit (the "Offering"), for aggregate gross proceeds to the Company of approximately CDN$4.44 million, before deducting Offering expenses and excluding any proceeds the Company may receive from the exercise of the underlying warrants. Pursuant to the Offering, the Company issued a total of 8,880,000 Units. Each Unit is comprised of one common share and one-half of one common share purchase warrant of the Company (each whole common share purchase warrant, a "Warrant"). Each Warrant entitles the holder thereof to acquire one common share of the Company (a "Warrant Share") at an exercise price of $0.65 per Warrant Share until the date that is three years following the initial closing date of the Offering.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Offering was made pursuant to an agency agreement (the "Agency Agreement") entered into between Bloom Burton Securities Inc., as sole agent (the "Agent"), and the Company dated May 21, 2026. An aggregate of 450,100 compensation warrants of the Company (each, a "Broker Warrant") were issued by the Company in connection with the Agency Agreement, each Broker Warrant entitling the holder to acquire one common share of the Company at an exercise price of $0.50 per share until the date that is two years following the initial closing date of the Offering.

The Offering was made pursuant to a prospectus supplement (the "Prospectus Supplement") dated May 21, 2026 to the Company’s existing short form base shelf prospectus dated June 4, 2025 (the "Base Shelf Prospectus") filed in the Provinces of British Columbia, Alberta and Ontario. The Units may also be offered in certain other jurisdictions outside of Canada, provided that a placement therein does not give rise to any prospectus, registration or continuous disclosure obligations on the part of the Company.

The Base Shelf Prospectus, the Agency Agreement and the Prospectus Supplement are available under the Company’s profile on SEDAR+ at www.sedarplus.ca.

The securities of the Company described above have not been and will not be registered under the United States Securities Act of 1933, as amended (the "1933 Act"), or any U.S. state securities laws and may not be offered or sold to, or for the account or benefit of, persons in the "United States" or "U.S. Persons" (as such terms are defined in Regulation S under the 1933 Act) except pursuant to an effective registration statement under the 1933 Act and applicable U.S. state securities laws or an available exemption from the registration requirements of the 1933 Act and applicable U.S. state securities laws.

In addition to the above Offering and as announced previously, the Company has entered into a separate structured financing of CDN$8.0 million with Sorbie Bornholm LP and Sorbie Investments LLP ("Sorbie").

This news release does not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor will there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

(Press release, Medicenna Therapeutics, MAY 28, 2026, View Source [SID1234666148])